Year None2024202320222021202020192018201720162015 Mar 25 Regeneron Provides Update on Biologics License Application for Odronextamab Mar 12 High School Seniors Win $1.8 Million at Regeneron Science Talent Search 2024 for Innovative Scientific Research on Artificial Intelligence, Cancer Metabolism and Mathematical Optimization Mar 11 Praluent® (alirocumab) Injection Receives FDA Approval to Treat Children with Genetic Form of High Cholesterol Mar 8 EYLEA® HD (aflibercept) Injection 8 mg Pivotal Data in Wet Age-related Macular Degeneration (wAMD) and Diabetic Macular Edema (DME) Published in The Lancet Feb 23 Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for Treatment of COPD with Type 2 Inflammation Feb 21 Linvoseltamab BLA for Treatment of Relapsed/Refractory Multiple Myeloma Accepted for FDA Priority Review Feb 16 Japan First in the World to Approve Dupixent® (dupilumab) for Chronic Spontaneous Urticaria (CSU) Feb 6 Regeneron Announces Investor Conference Presentations Feb 2 Regeneron Reports Fourth Quarter and Full Year 2023 Financial and Operating Results Feb 2 Linvoseltamab Receives EMA Filing Acceptance for Treatment of Relapsed/Refractory Multiple Myeloma First page « Previous page ‹ Page 1 Page 2 Page 3 Page 4 Page 5 Current page 6 Page 7 Next page › Last page »